Contineum Therapeutics Inc. - Ordinary Shares - Class A
CTNM
Get informed when a big investor buys or sells
+ FollowMarket Cap$646.71M
Close$
$2.43
83.3% downside
Current Fair Value
83.3% downsideOvervalued by 83.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $646.71 Million |
|---|---|
| Enterprise Value | $638.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.17 |
| Beta | 0.74 |
| Outstanding Shares | 37,467,840 |
Return
| Return on Equity | -24.02% |
|---|---|
| Return on Assets | -22.99% |
| Return on Invested Capital | -27.26% |
Valuation & Multiples
| P/E Ratio | -9.94 |
|---|---|
| PEG | 179.89 |
| Price to Sales | - |
| Price to Book Ratio | 2.42 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.61 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$5.65 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 137.25% |
|---|---|
| Total Calls | 11,300▲ 10.78% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.30%▲ 14.39% |
|---|---|
| Total Invested | $398.93M▲ 17.93% |
| Investors Holding | 91▲ 9.00% |
ESG Score
No data